Current Press Releases
Experts issue recommendations to provide gender-affirmation treatment for transgender individuals
September 13, 2017
|Contact: Jenni Glenn Gingery
Associate Director, Communications and Media Relations
|Contact: Colleen Williams
Manager, Public Relations
Endocrine Society calls on policymakers to consider biological underpinning to gender identity
Washington, DC - The Endocrine Society today issued a Clinical Practice Guideline on the treatment for gender-dysphoric/gender-incongruent people, commonly referred to as transgender, to develop the physical characteristics of the affirmed gender.
The guideline, entitled “Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline,” was published online and will appear in the November 2017 print issue of the Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of the Endocrine Society.
Over the last few decades, there has been a rapid expansion in the understanding of gender identity along with the implications for the care of transgender individuals. The new guideline establishes a framework for the appropriate treatment of these individuals and standardizes terminology to be used by healthcare professionals.
Many transgender individuals are prescribed hormone therapy to reduce the distress caused by having a gender identity that is different from the sex assigned at birth. Endocrinologists—specialists who untangle complex symptoms to diagnose, treat, research or cure hormone-related conditions—play a key role in treating transgender individuals, but a broader healthcare team is needed to provide mental health services and other treatments, such as gender-affirmation surgery.
“Diagnosing clinicians, mental health providers for adolescents, and mental health professionals for adults all should be knowledgeable about the diagnostic criteria for gender-affirming treatment, have sufficient training and experience in assessing related mental health conditions, and be willing to participate in the ongoing care throughout the endocrine transition,” said Wylie Hembree, MD, of the College of Physicians and Surgeons at Columbia University and chair of the task force that authored the guideline.
The Endocrine Society recommends gender-dysphoric/gender-incongruent persons receive a safe and effective hormone regimen that will suppress the body’s sex hormone secretion, determined at birth and manifested at puberty, and maintain levels of sex steroids within the normal range for the person’s affirmed gender.
Other recommendations from the guideline include:
- Hormone treatment is not recommended for pre-pubertal gender-dysphoric /gender-incongruent persons;
- For the care of youths during puberty and older adolescents, an expert multi-disciplinary team comprised of medical professionals and mental health professionals should manage treatment;
- For adult gender-dysphoric/gender-incongruent persons, the treating clinicians (collectively) should have expertise in transgender-specific diagnostic criteria, mental health, primary care, hormone treatment, and surgery, as needed by the patient;
- All individuals seeking gender-affirming medical treatment should receive information and counsel on options for fertility preservation prior to initiating puberty suppression in adolescents and prior to treating with hormonal therapy in both adolescents and adults;
- Removal of gonads may be considered when high doses of sex steroids are required to suppress the body’s secretion of hormones, and/or to reduce steroid levels in advanced age; and
- During sex steroid treatment, clinicians should monitor, in both transgender males (female to male) and/or transgender females (male to female), prolactin, metabolic disorders, and bone loss, as well as cancer risks in individuals who have not undergone surgical treatment.
Because many barriers to improving the health and well-being of transgender patients remain, the Endocrine Society issued a position statement today that calls on federal and private insurers to cover medical interventions for transgender individuals as prescribed by a physician.
The position statement highlights a durable biological underpinning to gender identity that should be considered in policy determinations and furthermore calls for increased funding for national research programs to close the gaps in knowledge regarding transgender medical care.
Other members of the Endocrine Society task force that developed this guideline include: Peggy T. Cohen-Kettenis and Louis Gooren of VU University Medical Center in Amsterdam, the Netherlands; Sabine E. Hannema of Leiden University Medical Centre in Leiden, the Netherlands; Walter J. Meyer of the University of Texas-Medical Branch at Galveston in Galveston, Tex.; M. Hassan Murad of the Mayo Clinic Evidence-based Practice Center in Rochester, Minn.; Stephen M. Rosenthal of the University of California San Francisco, Benioff Children’s Hospital in San Francisco, Calif.; Joshua D. Safer of Boston University School of Medicine in Boston, Mass.; Vin Tangpricha of Emory University School of Medicine in Atlanta, Ga.; and Guy G. T’Sjoen of Ghent University Hospital in Ghent, Belgium.
The Society established the Clinical Practice Guideline Program to provide endocrinologists and other clinicians with evidence-based recommendations in the diagnosis and treatment of endocrine-related conditions. Each guideline is created by a task force of topic-related experts in the field. Task forces rely on evidence-based reviews of the literature in the development of guideline recommendations. The Endocrine Society does not solicit or accept corporate support for its Clinical Practice Guidelines. All guidelines are supported entirely by Society funds.
The new guideline is co-sponsored by the American Association of Clinical Endocrinologists, American Society of Andrology, European Society for Paediatric Endocrinology, European Society of Endocrinology, Pediatric Endocrine Society and the World Professional Association for Transgender Health.
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.